News from sanofi A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jul 29, 2019, 08:00 ET Sanofi delivered solid growth in Q2 2019

Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q2 2019 Change Change at CER H1 2019 Change Change at CER IFRS net sales reported €8,628m +5.5% +3.9% €17,019m +5....


Jul 03, 2019, 08:00 ET Easing the Burden for People with Hemophilia

As recently as five years ago, effectively managing hemophilia meant frequent therapy infusions to prevent uncontrolled bleeding, limitations on...


Jun 26, 2019, 13:30 ET FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for use with other medicines to treat chronic rhinosinusitis with...


May 15, 2019, 17:00 ET Sanofi oncology pipeline targeting various cancers highlighted at ASCO 2019

Sanofi's oncology franchise and robust pipeline will be featured at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, delivering...


May 08, 2019, 13:12 ET Sanofi Recognized by DiversityInc as a Top 50 Company

For the second consecutive year, Sanofi has been named to DiversityInc's 2019 Top 50 Companies for Diversity. The DiversityInc Top 50 list recognizes ...


May 01, 2019, 18:35 ET FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas

The U.S. Food and Drug Administration (FDA) approved Dengvaxia® (Dengue Tetravalent Vaccine, Live) for the prevention of dengue disease caused by...


Apr 26, 2019, 08:05 ET Sanofi delivers strong Q1 2019 business EPS growth of 9.4% at CER

Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q1 2019 Change Change at CER IFRS net sales reported €8,391m +6.2% +4.2% IFRS net income reported €1,137m +11.9%...


Apr 17, 2019, 10:11 ET Sanofi Named One of America's Best Employers by Forbes

Forbes has named Sanofi one of America's Best Employers. This is the first time Sanofi has appeared on the Forbes list. "It is an amazing...


Apr 17, 2019, 07:00 ET World Hemophilia Day: Sanofi Genzyme Donation Impacts Patients Across the Globe

On World Hemophilia Day April 17th, the global bleeding disorders community unites to raise awareness and understanding of hemophilia and areas of...


Apr 10, 2019, 05:00 ET Sanofi provides unprecedented access to its insulins for one set monthly price

Starting in June, Sanofi will further expand its innovative Insulins Valyou Savings Program so people living with diabetes in the United States can...


Mar 11, 2019, 15:45 ET FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents

The U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe...


Feb 27, 2019, 16:17 ET FDA expands indication for Soliqua® 100/33

The U.S. Food and Drug Administration (FDA) has approved the expanded use of Soliqua® 100/33 (insulin glargine and lixisenatide injection) 100...


Feb 11, 2019, 07:00 ET Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price

Praluent® (alirocumab) will be made available at a new reduced U.S. list price of $5,850 annually, a 60% reduction from the original price, for both...


Feb 07, 2019, 08:00 ET Sanofi delivers 2018 business EPS growth of 5.1% at CER

Sanofi (NASDAQ: SNY; EURONEXT: SAN) Q4 2018 Change Change at CER 2018 Change Change at CER IFRS net sales reported €8,997m +3.5% +3.9% €34,463m -1.7% ...


Feb 06, 2019, 11:53 ET FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for...


Jan 30, 2019, 07:00 ET Sanofi Presents Research Advances in Rare Genetic Diseases at 15th Annual WORLDSymposium™ 2019

Continued research and development is critical to advancing care for people with rare diseases who have a significant need for earlier diagnosis,...


Jan 23, 2019, 14:53 ET FDA approves use of 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) in children as young as 6 months of age

The U.S. Food and Drug Administration has approved the use of the 0.5 mL dose of Fluzone® Quadrivalent (influenza vaccine) to include children age 6...


Jan 14, 2019, 16:47 ET FDA Approves Expanded Use of Adacel® (Tdap) Vaccine for Repeat Vaccination

The U.S. Food and Drug Administration has approved the expanded use of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis...


Jan 09, 2019, 17:00 ET New England Journal of Medicine publishes positive results of the pivotal trial of Cablivi® (caplacizumab) for rare blood clotting disorder

The New England Journal of Medicine (NEJM) today published positive results of the Phase 3 trial of Cablivi® (caplacizumab) in adults with acquired...


Dec 18, 2018, 16:30 ET Sanofi to Transfer U.S. Stock Exchange Listing to Nasdaq

Sanofi today announced that it will be transferring the listing of its American Depositary Shares (ADS) from the New York Stock Exchange (NYSE) to...


Nov 13, 2018, 22:20 ET Sanofi holds China Health Road Symposium at CIIE

At the first China International Import Expo, Sanofi, the world's leading healthcare company, said during the China Health Road Symposium, that with...


Nov 11, 2018, 08:15 ET ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause

New analyses on mortality from the 18,924-patient ODYSSEY OUTCOMES trial were presented at the American Heart Association (AHA) Scientific Sessions...


Nov 07, 2018, 17:00 ET New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial

The New England Journal of Medicine (NEJM) today published positive detailed results of the 18,924-patient ODYSSEY OUTCOMES trial. The trial met its...


Nov 06, 2018, 08:00 ET FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis

The U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent®...


Nov 01, 2018, 07:57 ET Sanofi expands Insulins VALyou Savings Program, helping more people living with diabetes

Sanofi has expanded its access program for people living with diabetes to include all Sanofi insulins*, helping patients get the insulin they need at ...